$1-per-pill alternative to Turing drug gets 'overwhelming' response: Imprimis CEO

Imprimis ($IMMY) CEO Mark Baum says response has been "overwhelming" to his company's $1-per-pill alternative to toxoplasmosis drug Daraprim, from the now-notorious Turing Pharmaceuticals, which raised its pill price to $750 each from $13.50 earlier this year. Report